GlaxoSmithKline Pharmaceuticals Limited has announced its Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. The company reported a slight decrease in revenue compared to the previous quarter. The board also noted the resignation of Non-Executive Director Mr. Subesh Williams and the appointment of Ms. Karine J F Natland as Non-Executive Director. Mr. Bhushan Akshikar has been re-appointed as Managing Director for a two-year term.
GlaxoSmithKline Pharmaceuticals: Q1 FY27 Financial Highlights
GlaxoSmithKline Pharmaceuticals Limited has disclosed its Un-audited Standalone and Consolidated Financial Results for the first quarter, ending June 30, 2026. The Board of Directors approved these results during a meeting held on August 3, 2026.
Standalone Financial Performance
For the quarter ended June 30, 2026, standalone revenue from operations stood at ₹92,442 Lakhs. Total income for the period was ₹98,605 Lakhs. Total expenses amounted to ₹64,807 Lakhs, leading to a profit before exceptional items and tax of ₹33,798 Lakhs. The profit for the period after tax was ₹25,333 Lakhs. Basic and diluted EPS before exceptional items were ₹14.95.
Consolidated Financial Performance
On a consolidated basis, revenue from operations for the quarter ended June 30, 2026, was ₹93,844 Lakhs. Total income reached ₹98,220 Lakhs. Total expenses were reported at ₹65,975 Lakhs. The profit before exceptional items and tax stood at ₹32,245 Lakhs, with a profit for the period after tax of ₹23,718 Lakhs. Basic and diluted EPS before exceptional items were ₹14.00.
Management Changes and Appointments
The Board meeting also addressed changes in the management structure. Mr. Subesh Williams (DIN: 07786724), a Non-Executive Director, has stepped down from the Board, effective from the closing hours of August 3, 2026, due to other professional commitments.
Ms. Karine J F Natland has been appointed as a Non-Executive Director, effective from August 3, 2026, or upon her obtaining the DIN, whichever is later. Ms. Natland is the SVP Asia Pacific (APAC) for GSK and joined the company in 2024 to lead product strategy for the General Medicines business. She has a strong background in the pharmaceutical industry with previous leadership roles at Organon and Merck & Co.
Furthermore, Mr. Bhushan Akshikar (DIN: 09112346) has been re-appointed as the Managing Director of the Company for a term of two years, commencing December 1, 2026.
Auditor’s Review
The interim financial results have undergone a limited review by the statutory auditors, Deloitte Haskins & Sells LLP. The auditors have issued a report stating that based on their review, nothing has come to their attention to suggest that the accompanying statements are not in compliance with the applicable accounting standards and regulations.
Source: BSE
